Real‐world treatment patterns and outcomes in non‐transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom

Objectives The treatment paradigm in newly diagnosed multiple myeloma (NDMM) is evolving toward individualized, risk‐directed, and longer duration of therapy (DOT). The objective of this study was to describe treatment patterns and outcomes in non‐transplant NDMM in four European countries. Methods...

Full description

Saved in:
Bibliographic Details
Published in:European journal of haematology 2020-09, Vol.105 (3), p.308-325
Main Authors: Mohty, Mohamad, Knauf, Wolfgang, Romanus, Dorothy, Corman, Shelby, Verleger, Katharina, Kwon, Youngmin, Cherepanov, Dasha, Cambron‐Mellott, M. Janelle, Vikis, Haris G., Gonzalez, Francisco, Gavini, Francois, Ramasamy, Karthik
Format: Article
Language:English
Subjects:
clinical practice patterns
Human health and pathology
Immunomodulation
Life Sciences
medical records
Multiple myeloma
Original
Proteasome inhibitors
retrospective studies
treatment outcomes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives The treatment paradigm in newly diagnosed multiple myeloma (NDMM) is evolving toward individualized, risk‐directed, and longer duration of therapy (DOT). The objective of this study was to describe treatment patterns and outcomes in non‐transplant NDMM in four European countries. Methods This retrospective chart review included adults with NDMM diagnosed between January 1, 2012, and December 31, 2013 (early cohort), or April 1, 2016, and March 31, 2017 (recent cohort). Results Among 836 patients, molecular testing was performed in 21% and 35% patients of early vs recent cohorts; proteasome inhibitor (PI)/alkylator combinations were the principal first‐line (1 L) therapy (39% vs 43%). Use of immunomodulatory drug (IMID)/alkylator combinations declined from early to recent cohort (26% vs 13%) but IMID (7% vs 16%) use increased. Few patients (5%) received 1 L maintenance therapy. Two‐thirds of patients were treated with a fixed duration intent, with a median 7‐month 1 L DOT and progression‐free survival (PFS) of 32.8 months in the early cohort. Both 1 L DOT and PFS were longer with oral compared to injectable regimens. Conclusions Although frontline treatment patterns changed significantly, 1 L DOT is short. The uptake of molecular testing and 1 L maintenance is low. These results highlight areas of unmet need in NDMM.
ISSN:0902-4441
1600-0609
DOI:10.1111/ejh.13439